reports
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CI...
PureCycle Technologies Third Quarter 2025 Corporate Update
PureCycle Technologies Third Quarter 2025 Corporate Update ORLANDO, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced today a corporate update for the third quarter ending September 30, 2025. Management Commentary PureCycle CEO Dustin Olson said, “The third quarter was one of continued growth for the Company. The Ironton Facility produced a record 7.2 million pounds of pellets, which is nearly equal to the amount produced in the first half of 2025.” Olson continued, “We now see momentum with brand owners and convert...
- Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FTNT FORTINET INC.
CNK CINEMARK HOLDINGS INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMD ADVANCED MICRO DEVICES INC.
ARVN ARVINAS HOLDING
LYFT LYFT
GOSS GOSSAMER BIO
DT DYNATRACE INC.
RVMD REVOLUTION MEDICINES
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
DASH DOORDASH
FHTX FOGHORN THERAPEUTICS
STX SEAGATE TECHNOLOGY HLDGS PLC
ALIT FOLEY TRASIMENE ACQUISITION CORP
APP APPLOVIN CORP
CCSI CONSENSUS CLOUD SOLUTIONS INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
DNTH DIANTHUS THERAPEUTICS INC
DBD DIEBOLD NIXDORF INCORPORATED
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Revolution Medicines Reports Third Quarter 2025 Financial Results and ...
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug De...
Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air® Secures Up to $32 Million to Accelerate Growth Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the p...
Revolution Medicines to Participate in November 2025 Investor Conferen...
Revolution Medicines to Participate in November 2025 Investor Conferences REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in two upcoming investor conferences. Details of the company’s participation are as follows: Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat: Tuesday, November 11 at 9:...
PureCycle Announces Appointment of a New Member to the Board of Direct...
PureCycle Announces Appointment of a New Member to the Board of Directors Dr. Siri Jirapongphan Joins PureCycle Board; Jeffrey R. Fieler Resigns as Director ORLANDO, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced today the appointment of Dr. Siri Jirapongphan to its board of directors, effective October 28, 2025. Dr. Jirapongphan currently serves as an independent director and Chairman of the Audit Committee of Bangkok Bank PLC. Additionally, he has served as Director and Treasurer of the Petroleum and Energy In...
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
OCUP OCUPHIRE PHARMA INC
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
HOWL INC
GMTX WEREWOLF THERAPEUTICS INC
SGMT GEMINI THERAPEUTICS INC
RNAC SAGIMET BIOSCIENCES INC
MAZE CARTESIAN THERAPEUTICS INC
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
Revolution Medicines to Report Financial Results for Third Quarter 202...
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financia...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib G...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to daraxonrasib, the company’s RAS(ON) multi-selective inhibitor, for the treatment of pancreatic cancer. “We are gratified the FDA has granted Orphan Dru...
- Wedbush Research
FATE FATE THERAPEUTICS INC
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
2303 UNITED MICROELECTRONICS CORP.
ROKU ROKU INC. CLASS A
TSEM TOWER SEMICONDUCTOR LTD
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
RZLT REZOLUTE
IMNM IMMUNOME
TNGX TANGO THERAPEUTICS
GFS INC
TYRA GLOBALFOUNDRIES INC
NUVL TYRA BIOSCIENCES INC
BCAX NUVALENT INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
PureCycle Schedules Third Quarter 2025 Corporate Update
PureCycle Schedules Third Quarter 2025 Corporate Update ORLANDO, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, will host a conference call on Thursday, November 6, 2025 to provide an update on recent corporate developments. A press release discussing such developments and other activity from the third quarter will be provided prior to the conference call. Third Quarter 2025 Conference Call Details Date: November 6, 2025 Time: 5:00 p.m. EST Participant Link: For participants interested in a listen-only webcast, please ...
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conf...
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its second fiscal quarter ended September 30, 2025 on Monday, November 10, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm E...
- Wedbush Research
TSLA TESLA INC
TPH TRI POINTE HOMES INC.
PEGA PEGASYSTEMS INC.
MELI MERCADOLIBRE INC.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
Revolution Medicines to Present Updated Elironrasib Safety and Efficac...
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior KRAS(OF...
- Wedbush Research
NVCR NOVOCURE LTD.
OSTK OVERSTOCK.COM INC.
ISR ISORAY
AAPL APPLE INC.
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
TLX TELIX PHARMACEUTICALS LIMITED
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
TLX TELIX PHARMACEUTICALS LIMITED
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.